Skip to main content
SpringerLink
Log in

Vitamine für das Auge?

Risiken und Chancen für Arzt und Patienten

Vitamins for the eyes?

Risks and opportunities for physician and patient

  • Originalien
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Die Beeinflussung der altersbedingten Makuladegeneration (AMD) sowie der diabetischen Retinopathie durch hierfür angebotene Produkte, oft als Nahrungsergänzungsmittel bezeichnet, und durch diätetische Maßnahmen wird diskutiert. Der Verkauf solcher Produkte in der ärztlichen Praxis ist nach dem ärztlichen Berufsrecht rechtswidrig. Die Ergebnisse aus der Age-Related Eye Disease Study (ARED-Studie) mit hochdosierten Vitaminen und Zink lassen sich nicht ohne weiteres auf andere Dosierungen und Stoffe übertragen. Außerdem bestehen gesundheitliche Risiken, die nicht ausreichend abgeklärt sind. Chancen für Arzt und Patienten können in einer Zulassung der AREDS-Formulierung als Arzneimittel liegen. Nach sorgfältiger Nutzen-Risiko-Abwägung und Prüfung im rechtlich für Arzneimittel vorgeschriebenen Zulassungsverfahren kann bei bestimmten Formen der AMD eine gewisse Schutzwirkung erwartet werden.

Abstract

This article discusses the effects of dietetic measures and specialized food supplements on age-related macular degeneration (AMD) and diabetic retinopathy. The sale of products in doctors’ offices is already prohibited by laws governing the medical profession. The results of the Age-Related Eye Disease Study (AREDS) concerning high doses of vitamins and zinc cannot simply be transferred to other doses and substances. Furthermore, there are health risks that have to be examined. Opportunities could arise for both doctor and patient if the AREDS formulation were granted authorization to be marketed as a medicinal product; however, a certain protective effect can be expected only for specific forms of AMD after a careful risk-benefit analysis and assessment within the statutory marketing authorization procedure for medicinal products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 119: 1417–1436

    Google Scholar 

  2. Bartlett H, Eperjesi F (2003) Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials. Ophthalmic Physiol Opt 23: 383–399

    Article  PubMed  Google Scholar 

  3. Bartlett HE, Eperjesi F (2007) Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. Eur J Clin Nutr 61: 1121–1127

    Article  PubMed  CAS  Google Scholar 

  4. Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (2007) Diätetische Lebensmittel. http://www.lgl.bayern.de/lebensmittel/warencodes/diaetetische_lebensmittel.htm

  5. Bone RA, Landrum JT, Dixon Z et al. (2000) Lutein and zeaxanthin in the eyes, serum and diet of subjects. Exp Eye Res 71: 239–245

    Article  PubMed  CAS  Google Scholar 

  6. Bundesärztekammer (2007) Bekanntmachungen. Wahrung der ärztlichen Unabhängigkeit Umgang mit der Ökonomisierung des Gesundheitswesens Hinweise und Erläuterungen beschlossen von den Berufsordnungsgremien der Bundesärztekammer am 2. April 2007. Dtsch Arztebl 104: A 1607

    Google Scholar 

  7. Bursell SE, Clermont AC, Aiello LP et al. (1999) High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22: 1245–1251

    Article  PubMed  CAS  Google Scholar 

  8. Bursell SE, King GL (1999) Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res Clin Pract 45: 169–182

    Article  PubMed  CAS  Google Scholar 

  9. Busch P, Hammes HP, Kerner W et al. (2006) Rauchen als Risikofaktor für mikroangiopathische Veränderungen bei erwachsenen Patienten mit Typ 1 Diabetes mellitus: Eine multizentrische Feldstudie. Diabetologie und Stoffwechsel 1: 305–310

    Article  Google Scholar 

  10. Cangemi FE (2007) TOZAL study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmology 7: 3

    Article  PubMed  Google Scholar 

  11. Chiarelli F, Santilli F, Sabatino G et al. (2004) Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy. Pediatr Res 56: 720–725

    Article  PubMed  CAS  Google Scholar 

  12. Chiu CJ, Taylor A (2007) Nutritional antioxidants and age-related cataract and maculopathy. Exp Eye Res 84: 229–245

    Article  PubMed  CAS  Google Scholar 

  13. Chong EWT, Wong TY, Kreis AJ et al. (2007) Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 335: 755–762

    Article  PubMed  Google Scholar 

  14. Clemons TE, Milton RC, Klein R et al. Age-Related Eye Disease Study Research Group (2005) Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS) AREDS Report No. 19. Ophthalmology 112: 533–539

    Article  PubMed  Google Scholar 

  15. Constable IJ (2004) Age-related macular degeneration and its possible prevention. Med J Aust 181: 471–472

    PubMed  Google Scholar 

  16. Evans JR (2006) Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2: CD000254

    PubMed  Google Scholar 

  17. FDA (2005) Qualified health claims: letter of denial – xangold lutein esters, lutein, or zeaxanthin and reduced risk of age-related macular degeneration or cataract formation (Docket No. 2004Q-0180)

  18. Giusti C, Gargiulo P (2007) Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci 11: 155–163

    PubMed  CAS  Google Scholar 

  19. Guymer RH, Chong EWT (2006) Modifiable risk factors for age-related macular degeneration. Med J Aust 184: 455–458

    PubMed  Google Scholar 

  20. Hodge WG, Schachter HM, Barnes D et al. (2006) Efficacy of omega-3 fatty acids in preventing age-related macular degeneration: a systematic review. Ophthalmology 113: 1165–1172

    Article  PubMed  Google Scholar 

  21. Johnson AR, Munoz A, Gottlieb JL, Jarrad DF (2007) High dose zinc increases hospital admissions due to genitourinary complications. J Urol 177: 639–643

    Article  PubMed  CAS  Google Scholar 

  22. Joussen AM (2007) Molekulare Pathogenese vaskulärer Erkrankungen des Auges – Anti-Angiogenese als Therapiekonzept. Dtsch Med Wochenschr 132: 1268–1272

    Article  PubMed  CAS  Google Scholar 

  23. Kassenärztliche Bundesvereinigung (2005) Bekanntmachungen: Beschluss einer Änderung der Richtlinien über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinien / AMR) vom 25. August 2005. Dtsch Arztebl 102: A-3363

    Google Scholar 

  24. Kassenärztliche Bundesvereinigung (2006) Bekanntmachungen: Vereinbarung von Qualitätssicherungsmaßnahmen nach § 135 Abs. 2 SGB V zur photodynamischen Therapie am Augenhintergrund (Qualitätssicherungsvereinbarung PDT). Dtsch Arztebl 103: A-2575

    Google Scholar 

  25. Kunisaki M, Bursell SE, Clermont AC et al. (1995) Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 269: E239–E246

    PubMed  CAS  Google Scholar 

  26. Lonn E, Bosch J, Yusuf S et al. HOPE and HOPE-TOO Trial Investigators (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer – a randomized controlled trial. JAMA 293: 1338–1347

    Article  PubMed  Google Scholar 

  27. Mares JA, LaRowe TL, Snodderly DM et al. CAREDS Macular Pigment Study Group and Investigators (2006) Predictors of optical density of lutein and zeaxanthin in retinas of older women in the carotenoids in age-related eye disease study, an ancillary study of the Women’s Health Initiative. Am J Clin Nutr 84: 1107–1122

    PubMed  CAS  Google Scholar 

  28. Mares-Perlman JA, Fisher AI, Klein R et al. (2001) Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol 153: 424–432

    Article  PubMed  CAS  Google Scholar 

  29. Miller ER, Pastor-Barriuso R, Dalal D et al. (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142: 37–46

    PubMed  CAS  Google Scholar 

  30. Moeller SM, Parekh N, Tinker L et al. CAREDS Research Study Group (2006) Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the carotenoids in age-related eye disease study (CAREDS): ancillary study of the Women’s Health Initiative. Arch Ophthalmol 124: 1151–1162

    Article  PubMed  CAS  Google Scholar 

  31. Mohamed Q, Gilles MC, Wong TY (2007) Management of diabetic retinopathy: a systematic review. JAMA 298: 902–916

    Article  PubMed  CAS  Google Scholar 

  32. National Eye Institute (2006) NEI statement. Lutein and its role in eye disease prevention. http://www.nei.nih.gov/news/statements/lutein.asp

  33. OLG Celle (2007) Urteil vom 21.12.2006, 13 U 118/06, „Verkürzter Versorgungsweg“/Abgabe von Brillen durch Augenärzte/Vermittlung von Patienten an Augenoptiker. MedR 25: 435–439

    Article  Google Scholar 

  34. Ollenschläger G, Kopp I, Thole H, Lelgemann M und für den Expertenkreis NVL Typ-2-Diabetes–Netzhautkomplikationen beim ÄZQ (2007) Die Nationale VersorgungsLeitlinie Typ-2-Diabetes–Netzhautkomplikationen. Med Klin 102: 153–156; http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_netzhaut/index_html

    Google Scholar 

  35. Pauleikhoff D (2003) Die Bedeutung von Antioxidantien und Spurenelementen bei der Entstehung und Prävention der altersabhängigen Makuladegeneration. Ernährung & Medizin 18: 105–110

  36. Peponis V, Papathanasiou M, Kapranou A et al. (2002) Protective role of oral antioxidant supplementation in ocular surface of diabetic patients. Br J Ophthalmol 86: 1369–1373

    Article  PubMed  CAS  Google Scholar 

  37. Pressemitteilungen des Bundesverwaltungsgerichts (2007) Bundesverwaltungsgericht grenzt Nahrungsergänzungsmittel von Arzneimitteln ab. BVerwG 3 C 21.06, 3 C 22.06, 3 C 23.06 – Urteil v. 25.07.2007. SächsVBl 11: II–III

    Google Scholar 

  38. Richer S, Devenport J, Lang JC (2007) LAST II: differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 78: 213–219

    PubMed  Google Scholar 

  39. Rosen R (2007) The Age-Related Eye Disease Study II (AREDS II): a multi-center, randomized trial of lutein, zeaxanthin, and long-chain omega-3 fatty acids (Docosahexaenoic acid [DHA] and Eicosapentaenoic acid [EPA]) in age-related macular degeneration. The New York Eye & Ear Infirmary. http: //www.nyee.edu/ctoph-areds.html

  40. Schalch W, Cohn W, Barker FM et al. (2007) Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin – the LUXEA (Lutein Xanthophyll Eye Accumulation) study. Arch Biochem Biophys 458: 128–135

    Article  PubMed  CAS  Google Scholar 

  41. Schmidt-Erfurth U (2005) Nutrition and retina. In: Augustin AJ (ed) Nutrition and the eye. Developments in Ophthalmology, Vol. 38. Karger, Basel pp 120–147

  42. Schweitzer D (2004) In vivo-detection of macular pigment and its effect by lutein supplementation. In: Ioseliani OR (ed) Focus on macular degeneration research. Nova Biomedical, Inc. Waltham pp 253–272

  43. Scientific Committee on Food (SCF) (2003) Opinion of the Scientific Committee on Food for the development of tolerable upper intake level of zinc. SCF/CS/NUT/UPPLEV/62 Final. (expressed on 5 March 2003). European Commission, Brüssel

  44. Seddon JM, George S, Rosner B, Klein ML (2006) CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered 61: 157–165

    Article  PubMed  CAS  Google Scholar 

  45. Seddon JM (2007) Multivitamin-multimineral supplements and eye disease: age-related macular degeneration and cataract. Am J Clin Nutr Suppl 85: 304S–307S

    CAS  Google Scholar 

  46. Toeller M (2005) Evidenz-basierte Ernährungsempfehlungen zur Behandlung und Prävention des Diabetes mellitus. Diabetes und Stoffwechsel 14: 75–94

    Google Scholar 

  47. Trieschmann M, Beatty S, Nolan JM et al. (2007) Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res 84: 718–728

    Article  PubMed  CAS  Google Scholar 

  48. Vainio H (2000) Chemoprevention of cancer: lessons to be learned from the beta-carotene trials. Toxicol Lett 112-113: 513–517

    Google Scholar 

  49. Ziemssen F, Warga M, Bartz-Schmidt KU, Wilhelm H (2005) „Haben Sie ein Mittel gegen Makuladegeneration?“ Eine Feldstudie in 60 deutschen Apotheken über die Beratung zu Nahrungsergänzungsmitteln. Ophthalmologe 102: 715–725

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Bundesinstitut für Risikobewertung (BfR), Thielallee 88–92, 14195, Berlin, Deutschland

    R. Großklaus & K.J. Henning

Authors
  1. R. Großklaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K.J. Henning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Großklaus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Großklaus, R., Henning, K. Vitamine für das Auge?. Ophthalmologe 106, 521–526 (2009). https://doi.org/10.1007/s00347-008-1819-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-008-1819-7

Schlüsselwörter

Keywords

Search

Navigation